NEW ASPECTS OF CLINICAL EFFECTIVENESS OF TYPE 5 PHOSPHOTIDYL ESTERASE INHIBITORS IN THE TREATMENT OF PATIENTS WITH ERECTILE DYSFUNCTION


Дәйексөз келтіру

Толық мәтін

Аннотация

Some new approaches to evaluating the effectiveness of vardenafil (Levitra) and other phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction are presented. In particular, along with traditional methods of assessing the clinical effects of Levitra, a number of studies have used a special technique that allowed to evaluate the effect of this drug on the satisfaction of the sexual life of female partners of patients. It was shown that Levitra increases the degree of their satisfaction with sexual intercourse. The reason for this is that treatment with Levitra is accompanied by significant increase in the duration of erection, including in patients with metabolic syndrome. The beneficial effects of vardenafil (Levitra) on the duration of erection and satisfaction of sex life partners of patients are additional confirmations of the high clinical efficacy of this drug.

Әдебиет тізімі

  1. Francis SH, Corbin JD. Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Curr Urol Rep 2003;4:457-65.
  2. Rotella DP. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov 2002;1:674-82.
  3. Montorsi F, Salonia A, Briganti A, et al. Vardenafil for the treatment of erectile dysfunction: a critical review of the literature based on personal clinical experience. Eur Urol 2005;47:612-21.
  4. Nehra A, Grantmyre J, Nadel A, et al. Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy. J Urol 2005;173:2067-71
  5. Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26:777-83.
  6. Wagner G, Fugl-Meyer KS, Fugl-Meyer AR. Impact of erectile dysfunction on quality of life: patient and partner perspectives. Int J Impot Res 2000;12(4):S144-46.
  7. Chevret M, Jaudinot E, Sullivan K, et al. Impact of erectile dysfunction (ED) on sexual life of female partners: assessment with the Index of Sexual Life (ISL) questionnaire. J Sex Marital Ther 2004;30:157-72.
  8. Fisher WA, Rosen RC, Eardley I, et al. Sexual experience of female partners of men with erectile dysfunction: the female experience of men's attitudes to life events and sexuality (FEMALES) study. J Sex Med 2005;2:675-84.
  9. Rosen RC, Fisher WA, Beneke M, Homering M, Evers T. The COUPLES-project: a pooled analysis of patient and partner treatment satisfaction scale (TSS) outcomes following vardenafil treatment. BJU Int 2007;99:849-59.
  10. Weiss P, Brody S. Women's partnered orgasm consistency is associated with greater duration of penile-vaginal intercourse but not of foreplay. J Sex Med 2009;6:135-41.
  11. Miller SA, Byers ES. Actual and desired duration of foreplay and intercourse: discordance and misperceptions within heterosexual couples. J Sex Res 2004;41:301-9.
  12. Rosenberg MT, Adams PL, McBride TA, et al. Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study. Int J Clin Pract 2009;63:27-34.
  13. Miner M, Gilderman L, Bailen J, et al. Vardenafil in men with stable statin therapy and dyslipidemia. J Sex Med 2008;5:1455-67.
  14. Мазо ЕБ, Гамидов СИ, Иремашвили ВВ, Гасанов РВ. Патогенез эректильной дисфункции при метаболическом синдроме // Вестник РАМН 2008. № 2. С. 21-6.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2012

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>